Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04479436 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04479436 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 40 participants.
The verdict
NCT04479436, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.
Interventions
- DRUG Patritumab Deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04479436
The ClinicalTrials.gov registry entry for NCT04479436 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patritumab Deruxtecan is the first listed.
NCT04479436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04479436 about?
NCT04479436 is a clinical study titled "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer". This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor...
What is the current status of trial NCT04479436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-09-14. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT04479436?
The interventions under investigation include: Patritumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT04479436?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.